Degradation of EZH2 by the PROTAC-degrader MS-177 effectively inhibited on-target EZH2-PRC2 and MYC-related oncogenic nodes and inhibited leukemia growth in vivo more effectively than enzymatic inhibition (55, 56). Here, EZH2 is linked to leukemia.